Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Invest in Cases Systematically - Every stock is handpicked
Start Buying Now
Start Buying Now
Nectar Lifesciences (NecLife), a fast growing manufacturer of generic active pharmaceutical ingredients (APls) and formulation products has achieved another significant milestone by receiving European cGMP (Current Good Manufacturing Practices) approval for its Cephalosporin formulations manufacturing facility in Baddi, Himachal Pradesh. This approval will facilitate the company's entry into lucrative 27 European Union member states, EEU, South Africa and Middle East markets on account of mutual recognition.
After receiving EU cGMP for API facility in October 2011, NecLife has received the European cGMP compliance certification for its Cephalosporin formulations facility in Baddi for injectables Cephalosporins. This approval has been received following the successful inspection by the Hungarian Authority - National Institute for Quality and Organizational Development in Healthcare and Medicines, National Institute of Pharmacy (GYEMSZI-OGYI) in June 2011. Hungary being a member of European Union, the GYEMSZI-OGYI Certificate is accepted by all EU Health Authorities and by authorities of several other countries.
NecLife's Formulations facility, Unit-VI, has received this approval for Cefotaxime sodium for injection, Ceftriaxone sodium for injection and Cefuroxime sodium for injection. Together these 3 products have a market potential in excess of $1 billion in the European countries.
Till date, NecLife has filed 27 Drug Master Files (DMFs) and 6 Abbreviated New Drug Applications (ANDAs). The company also has an ambitious plan of filing over 20 DMFs and multiple ANDAs/EU dossiers in US and EU markets in year 2012. These filings by NecLife will result in robust topline as well as bottom-line for the company from year 2013 onwards in view of gestation period for regulatory approvals, which take significant time in view of the current pendency.
Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1515.00 |
| Dr. Reddys Lab | 6080.25 |
| Cipla | 1565.50 |
| Zydus Lifesciences | 1110.95 |
| Lupin | 1601.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
